# An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

> **NCT03749447** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 270 (actual)

## Conditions studied

- Chronic Kidney Diseases
- Alport Syndrome
- Autosomal Dominant Polycystic Kidney

## Interventions

- **DRUG:** Bardoxolone methyl

## Key facts

- **NCT ID:** NCT03749447
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-08
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 270 (ACTUAL)
- **Why stopped:** Discontinuation of all bardoxolone chronic kidney disease programs
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749447, "An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03749447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*